CATX
Perspective Therapeutics Inc
AMEX · Biotechnology
$4.71
+0.08 (+1.73%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 2.57M | 5.02M | 71.95M | 70.28M | 78.45M |
| Net Income | -140,182,672 | -246,174,448 | -11,935,296 | -10,926,196 | -10,214,084 |
| EPS | — | — | — | — | — |
| Profit Margin | -5,452.5% | -5,179.9% | -16.6% | -15.6% | -13.0% |
| Rev Growth | -48.8% | -48.8% | -9.3% | +8.8% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.55M | 1.55M | 146.40M | 184.55M | 188.23M |
| Total Equity | 266.72M | 266.72M | 273.33M | 242.97M | 259.56M |
| D/E Ratio | 0.01 | 0.01 | 0.54 | 0.76 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -156,620,475 | -290,320,880 | -19,768,936 | -18,107,687 | -17,982,441 |
| Free Cash Flow | — | — | -4,863,546 | -6,087,830 | -8,175,378 |